For Subscribers

Get the complete article now!

TWST: What do you (Nasdaq:GLGC) expect about three years from now?

Mr. Gessler: Right now we are sticking to our knitting around the subscription-based business that we have and selling subscriptions of all types to the GeneExpress Suite. We are moving that forward as aggressively as possible. This is selling into the pharmaceutical and biotech companies. We do that on an annual subscription basis and it typically runs 4 million for the large pharma, 2 million and up for the biotech companies and we are going to continue to pursue that. We think that we can really expand our book of business dramatically in the years ahead. What we are also looking all the time to do is expand the kind of content that we have. We have a fundamentally valuable underlying asset in what we call our BioRepository, or tissue bank, essentially. It is this collection of these 30,000 human samples that we are assembling.

TWST: How is the money situation this year?

Mr. Gessler: This is a content business and it is also time sensitive. It is all about making an early move in this marketplace and building a large-scale database as quickly as possible, and really to make it much more difficult for your competitors to move into the space. We are hitting on that very aggressively. We are building this database as rapidly as is possible, and we are going to continue to do that. It is always a judgment call. I use the analogy of a movie producer: It is producing the movie. How much are you going to spend on it to really bring the people into the movie theaters? We need to do the same thing. It is all about the content that we have. We need to build that and have the breadth and depth of content, the kind of content, that our clients want that will bring them to us so they want to continue with our software and they want to up their subscriptions to even larger sets of data.

TWST: Did you lose a little money this year?

Mr. Gessler: Yes, absolutely. We are still in a position where we are effectively losing money on an annual basis. We think that we are probably several years from profitability. We want to build the business, build the franchise and the front end of this, and look forward to the opportunities that lay ahead for us. It is a huge fixed cost business. Once we run the samples and put the data into our database, but in a sense, reaping all the rewards of continually selling each and every one of those data points as effectively as we possibly can in the future.

TWST: Are you in a pretty good cash position?

Mr. Gessler: Yes, absolutely. We were very pleased with the opportunity that we had the first of the year. We were the first company to come out in what turned out to be a monumental year for biotech. We were able to raise about 270 million at that time. We are presently in a cash position at the end of the third quarter with about 230 million. Our burn rate is relatively low. We have the kind of cash position that enables us to move forward with our business and our strategy, and be in a comfortable position to execute on that effectively.